rubicon like autophagy enhancerGenealiases: C13orf18 · KIAA0226L · PACER
Q-omics provides the consensus-scored RUBCNL profile across patient tissues and cancer cell-line models. RUBCNL expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RUBCNL is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RUBCNL RNA expression shows 21,107 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, KIRC, and LSCC as cancer lineages where RUBCNL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RUBCNL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RUBCNL survival associations across molecular data types. RUBCNL RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RUBCNL RNA expression–survival associations across cancer types. High RUBCNL expression shows unfavorable associations in LGG and KIRC, but favorable associations in LUAD, HNSC, UCEC and COAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RUBCNL RNA expression.
This table summarizes RUBCNL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RUBCNL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RUBCNL shows lower tumor expression in BRCA, LUSC and KICH and higher tumor expression in KIRC, COAD and HNSC. The KIRC box plot shows higher RUBCNL RNA expression in tumor versus normal tissue (log2 FC = +0.919, t-test p < 0.001).
This table shows molecular features associated with RUBCNL in patient tissues and cancer cell lines. In patient samples, RUBCNL shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RUBCNL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
